[go: up one dir, main page]

WO2002026780A3 - Polypeptides contenant un domaine paad, acides nucleiques codant ces polypeptides, et procedes d'utilisation - Google Patents

Polypeptides contenant un domaine paad, acides nucleiques codant ces polypeptides, et procedes d'utilisation Download PDF

Info

Publication number
WO2002026780A3
WO2002026780A3 PCT/US2001/030160 US0130160W WO0226780A3 WO 2002026780 A3 WO2002026780 A3 WO 2002026780A3 US 0130160 W US0130160 W US 0130160W WO 0226780 A3 WO0226780 A3 WO 0226780A3
Authority
WO
WIPO (PCT)
Prior art keywords
paad
domain
methods
polypeptides
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/030160
Other languages
English (en)
Other versions
WO2002026780A2 (fr
Inventor
John C Reed
Adam Godzik
Zhi-Liang Chu
Krzysztof Pawlowski
Loredana Fiorentino
Maria E Ariza
Christian Stehlik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2001296333A priority Critical patent/AU2001296333A1/en
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Priority to AU9633301A priority patent/AU9633301A/xx
Publication of WO2002026780A2 publication Critical patent/WO2002026780A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002026780A3 publication Critical patent/WO2002026780A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des molécules d'acide nucléique isolées codant pour des polypeptides contenant un domaine PAAD et des fragments fonctionnels de ces derniers, notamment des fragments contenant des domaines PAAD, des domaines NB-ARC et des domaines LRR, des polypeptides codés, et des anticorps. L'invention concerne également des procédés d'identification de polypeptides et d'agents qui s'associent à un polypeptide contenant un domaine PAAD ou à un fragment de ce dernier, ou qui modifient une association de polypeptides contenant un domaine PAAD. L'invention concerne également des procédés d'identification d'agents qui modulent l'inhibition de l'activité de NFkB à médiation assurée par un domaine PAAD, ou qui modulent une activité d'un domaine NB-ARC d'un polypeptide contenant un domaine PAAD. L'invention concerne également des procédés de modulation de l'activité transcriptionnelle de NFkB dans une cellule, ainsi que des procédés de modification de l'expression d'un polypeptide contenant un domaine PAAD dans une cellule.
PCT/US2001/030160 2000-09-26 2001-09-26 Polypeptides contenant un domaine paad, acides nucleiques codant ces polypeptides, et procedes d'utilisation Ceased WO2002026780A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001296333A AU2001296333A1 (en) 2000-09-26 2001-09-25 Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
AU9633301A AU9633301A (en) 2000-09-26 2001-09-26 Paad domain-containing polypeptides, encoding nucleic acids, and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67176000A 2000-09-26 2000-09-26
US09/671,760 2000-09-26

Publications (2)

Publication Number Publication Date
WO2002026780A2 WO2002026780A2 (fr) 2002-04-04
WO2002026780A3 true WO2002026780A3 (fr) 2003-05-22

Family

ID=24695772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/030160 Ceased WO2002026780A2 (fr) 2000-09-26 2001-09-26 Polypeptides contenant un domaine paad, acides nucleiques codant ces polypeptides, et procedes d'utilisation

Country Status (2)

Country Link
AU (2) AU2001296333A1 (fr)
WO (1) WO2002026780A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7041643B2 (en) 2001-01-31 2006-05-09 Millennium Pharmaceuticals, Inc. Molecules of the PYRIN/NBS/LRR protein family and uses thereof
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
DE10202419A1 (de) 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
US11512326B2 (en) 2009-05-26 2022-11-29 University Of Florida Research Foundation, Incorporated Small angiotensin peptide expression system in mammalian cells
CA2940513C (fr) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivrance d'une proteine a domaine de recrutement des caspases (card) en tant que therapie pour inflammation oculaire
US11053291B2 (en) 2014-02-19 2021-07-06 University Of Florida Research Foundation, Incorporated Delivery of Nrf2 as therapy for protection against reactive oxygen species
ES2911714T3 (es) 2014-03-11 2022-05-20 Univ Florida Proteína M013 expresada por AAV como un terapéutico antiinflamatorio para su uso en un método de tratamiento de enfermedad ocular inflamatoria
GB201815045D0 (en) 2018-09-14 2018-10-31 Univ Ulster Bispecific antibody targeting IL-1R1 and NLPR3
CN111690687B (zh) * 2020-07-28 2021-12-21 华南农业大学 促进骨骼肌发育的方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061005A2 (fr) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Nouvelles molecules de la famille de proteines du domaine pyrine, et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061005A2 (fr) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Nouvelles molecules de la famille de proteines du domaine pyrine, et leurs utilisations

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ARAVIND L ET AL: "The domains of death: evolution of the apoptosis machinery", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 24, no. 2, 1 February 1999 (1999-02-01), pages 47 - 53, XP004167901, ISSN: 0968-0004 *
BERTIN J ET AL: "THE PYRIN DOMAIN: A NOVEL MOTIF FOUND IN APOPTOSIS AND INFLAMMATION PROTEINS", CELL DEATH AND DIFFERENTIATION, EDWARD ARNOLD, OXFORD, GB, vol. 12, no. 7, December 2000 (2000-12-01), pages 1273 - 1274, XP008006072, ISSN: 1350-9047 *
DATABASE EMBL 1 December 1992 (1992-12-01), KAWANOMOTO M ET AL: "Ribonuclease inhibitor", XP002212418 *
DATABASE EMBL 26 January 2000 (2000-01-26), BIRREN B ET AL: "Homo sapiens clone RP11-394L10", XP002212594 *
DATABASE EMBL 26 November 2001 (2001-11-26), MARTINON F ET AL: "NALP4 a novel member of the PYD, NACHT, and LRR family", XP002212419 *
FAIRBROTHER W J ET AL: "THE PYRIN DOMAIN: A MEMBER OF THE DEATH DOMAIN-FOLD SUPERFAMILY", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 9, no. 10, September 2001 (2001-09-01), pages 1911 - 1918, XP008006069, ISSN: 0961-8368 *
INOHARA N ET AL: "Genes with homology to mammalian apoptosis regulators identified in zebrafish.", CELL DEATH AND DIFFERENTIATION, vol. 7, no. 5, May 2000 (2000-05-01), pages 509 - 510, XP002212414, ISSN: 1350-9047 *
KOONIN E V ET AL: "The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 25, no. 5, May 2000 (2000-05-01), pages 223 - 224, XP004198165, ISSN: 0968-0004 *
MARTINON F ET AL: "The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation.", CURRENT BIOLOGY: CB. ENGLAND 20 FEB 2001, vol. 11, no. 4, 20 February 2001 (2001-02-20), pages R118 - R120, XP002212417, ISSN: 0960-9822 *
MASUMOTO J ET AL: "ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 48, 26 November 1999 (1999-11-26), pages 33835 - 33838, XP002191744, ISSN: 0021-9258 *
PAWLOWSKI K ET AL: "PAAD - a new protein domain associated with apoptosis, cancer and autoimmune diseases.", TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND FEB 2001, vol. 26, no. 2, February 2001 (2001-02-01), pages 85 - 87, XP002212415, ISSN: 0968-0004 *
STAUB E ET AL: "The DAPIN family: a novel domain links apoptotic and interferon response proteins.", TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND FEB 2001, vol. 26, no. 2, February 2001 (2001-02-01), pages 83 - 85, XP002212416, ISSN: 0968-0004 *

Also Published As

Publication number Publication date
AU2001296333A1 (en) 2002-04-08
AU9633301A (en) 2002-04-08
WO2002026780A2 (fr) 2002-04-04

Similar Documents

Publication Publication Date Title
WO2002026780A3 (fr) Polypeptides contenant un domaine paad, acides nucleiques codant ces polypeptides, et procedes d'utilisation
WO2000031124A3 (fr) Peptides modulant l'interaction des ephrines de classe b avec les domaines pdz
WO2005051998A3 (fr) Anticorps
EP1097162A4 (fr) Oligonucleotides comportant des liaisons internucleosidiques phosphothioate chirales a des sites specifiques
WO2000034308A3 (fr) Systeme de transduction de proteines et methodes d'utilisation
WO2002012325A3 (fr) Genes suppresseurs
WO2004053059A3 (fr) Polypeptide de « mitoneet » provenant de membranes mitochondriales, modulateurs correspondants, et leurs methodes d'utilisation
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
DK1082423T3 (da) Cyclin E2-gener og -proteiner
WO2004003172A3 (fr) Gene esm-1 exprime differentiellement dans l'angiogenese, antagonistes de dernier et methodes d'utilisation correspondantes
WO2001036604A3 (fr) Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
WO2001051523A3 (fr) Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
WO2001016317A3 (fr) Molecules induites par un hydrocarbure aromatique polycyclique
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
WO2001066752A3 (fr) Genes specifiques de la reproduction
AP9901510A0 (en) Polypeptides comprising gax protein domains, involved in repressing transcription and or interacting with other proteins corresponding nucleic acids andtheir use.
WO2001090156A3 (fr) Polypeptides contenant un domaine card, acides nucleiques de codage, et methodes d'utilisation
WO2001070808A3 (fr) Proteines associees a l'angiogenese et acides nucleiques codant ces proteines
FI980782L (fi) Epiteelisoluihin sitoutuva proteiinialue ja sitä koodaava DNA-sekvenssi
WO2004110356A3 (fr) Methodes de modulation de l'adhesion de cellule a cellule a l'aide d'un agoniste d'activite proteique de type c1inh
WO2005111070A3 (fr) Domaines de type de mucine3 egf
AU2001276488A1 (en) Pleckstrin homology polypeptides and dna encoding such
WO2003006680A3 (fr) Omi et domaines d'omi interrompant l'interaction iap-caspase
DE59813125D1 (de) Srcr domäne-enthaltendes protein
WO2002048353A3 (fr) Sequences d'adn codant pour une proteine de transduction du signal d'apoptose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP